Search

C16H11BF2N2, monoclinic, P21/c (no. 14), a = 9.0978(14) Å, b = 18.580(3) Å, c = 15.476(2) Å, β = 99.516(5)°, V = 2580.0(7) Å3, Z = 8, Rgt(F) = 0.0406, wRref(F2) = 0.1307, T = 193 K. [ABSTRACT FROM AUTHOR]

C21H25EuN2O10, monoclinic, P21/n (no. 14), a = 14.1635(8) Å, b = 12.1381(6) Å, c = 14.4528(7) Å, β = 104.361(2)°, V = 2407.1(2) Å3, Z = 4, Rgt(F) = 0.0304, wRref(F2) = 0.0893, T = 296 K. [ABSTRACT FROM AUTHOR]

C16H11BF2N2, monoclinic, P21/c (no. 14), a = 9.0978(14) Å, b = 18.580(3) Å, c = 15.476(2) Å, β = 99.516(5)°, V = 2580.0(7) Å3, Z = 8, Rgt(F) = 0.0406, wRref(F2) = 0.1307, T = 193 K. [ABSTRACT FROM AUTHOR]

C32H50Eu2N16O24, monoclinic, P21/c (no. 14), a = 7.685(5) Å, b = 13.482(5) Å, c = 23.240(5) Å, β = 93.578(5)°, V = 2403.2(19) Å3, Z = 2, Rgt(F) = 0.0235, wRref(F2) = 0.0577, T = 293 K. [ABSTRACT FROM AUTHOR]

C18H15BN2O2, monolinic, P21/n (no. 14), a = 13.61(2) Å, b = 7.389(11) Å, c = 16.34(2) Å, β = 113.91(2)°, V = 1502(4) Å3, Z = 4, Rgt(F) = 0.0544, wRref(F2) = 0.1651, T = 273 K. [ABSTRACT FROM AUTHOR]

C18H15BN2O2, monolinic, P21/n (no. 14), a = 13.61(2) Å, b = 7.389(11) Å, c = 16.34(2) Å, β = 113.91(2)°, V = 1502(4) Å3, Z = 4, Rgt(F) = 0.0544, wRref(F2) = 0.1651, T = 273 K. [ABSTRACT FROM AUTHOR]

C18H17BN2O2, monoclinic, P21/c (no. 14), a = 12.5782(14) Å, b = 13.6724(14) Å, c = 8.7113(9) Å, β = 97.819(6)°, V = 1484.2(3) Å3, Z = 4, Rgt(F) = 0.0482, wRref(F2) = 0.1357, T = 193 K. [ABSTRACT FROM AUTHOR]

C18H15BN2O2, monoclinic, P21/c (no. 14), a = 6.8522(9) Å, b = 8.4333(11) Å, c = 13.1908(18) Å, β = 95.880(5)°, V = 758.24(17) Å3, Z = 2, Rgt(F) = 0.0381, wRref(F2) = 0.1068, T = 193 K. CCDC no.: 2045109 [ABSTRACT FROM AUTHOR]

C17H13BN2O2, orthorhombic, Pbca (no. 61), a = 10.0820(14) Å, b = 13.1135(19) Å, c = 20.644(3) Å, V = 2729.4 Å3, Z = 8, Rgt(F) = 0.0373, wRref(F2) = 0.1005, T = 193 K. [ABSTRACT FROM AUTHOR]

C18H17BN2O2, monoclinic, P21/c (no. 14), a = 12.5782(14) Å, b = 13.6724(14) Å, c = 8.7113(9) Å, β = 97.819(6)°, V = 1484.2(3) Å3, Z = 4, Rgt(F) = 0.0482, wRref(F2) = 0.1357, T = 193 K. [ABSTRACT FROM AUTHOR]

C18H15BN2O2, monoclinic, P21/c (no. 14), a = 6.8522(9) Å, b = 8.4333(11) Å, c = 13.1908(18) Å, β = 95.880(5)°, V = 758.24(17) Å3, Z = 2, Rgt(F) = 0.0381, wRref(F2) = 0.1068, T = 193 K. CCDC no.: 2045109 [ABSTRACT FROM AUTHOR]

C17H13BN2O2, orthorhombic, Pbca (no. 61), a = 10.0820(14) Å, b = 13.1135(19) Å, c = 20.644(3) Å, V = 2729.4 Å3, Z = 8, Rgt(F) = 0.0373, wRref(F2) = 0.1005, T = 193 K. [ABSTRACT FROM AUTHOR]

A series of asymmetrically disubstituted liquid crystalline compounds with high birefringence based on phenyldiacetylenes was synthesised by coupling of intermediate molecules with a phenylacetylene fragment. The structures of the intermediates and resulting compounds were confirmed by Fourier transform infrared, 1H nuclear magnetic resonance and Matrix assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry. Their liquid crystalline behaviour, including transition temperatures and phase sequences, was investigated by differential scanning calorimetry and polarising optical microscopy. As an important parameter, the birefringence was also measured, using polarising light interferometry. The results indicated that the compounds exhibited different liquid crystalline phases in the high temperature region, with high birefringence values. In addition, the selective reflection characteristics associated with birefringence under conditions which maintained the matrix nematic liquid crystal and the concentration of chiral dopant were studied. [ABSTRACT FROM AUTHOR]